VASCVERSA
Dead / Abandoned — Abandoned — failure to respond (as of 01 Oct 2026)
What this means for you
This application is over — abandoned 18 Sept 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 79436736
- Mark type
- Word mark
- Filed
- 30 Sept 2025
- Abandoned
- 18 Sept 2026
Goods and services
- Class 001 — Chemicals: Stem cells for research purposes; stem cells for scientific purposes; chemicals for use in manufacturing pharmaceuticals; reagents for research purposes; reagents for medical research; reagents for scientific purposes; diagnostic reagents for scientific or research use; cell culture reagents for scientific and research use; blood culture media for scientific use.
- Class 005 — Pharmaceuticals: Pharmaceuticals; drugs for medical purposes; stem cells; pharmaceutical preparations containing stem cells; stem cells for medical purposes; cells for medical use; cell growth media for growing cells for medical use; living cells for medical use; cellular function activating agents for medical purposes; vaccines, reagents for medical use; medical diagnostic reagents; biological tissue cultures for medical purposes; human allograft tissue; tissues for medical use; vascular grafts; sponges for healing wounds.
- Class 010 — Medical apparatus: Medical devices; medical apparatus; medical instruments; apparatus for the regeneration of stem cells for medical purposes; medical devices and apparatus for vascular regeneration and repair; medical devices and apparatus for cell therapy; blood testing equipment; blood testing apparatus; artificial vascular grafts.
- Class 042 — Scientific and technological services: Medical and pharmacological research services; stem cell research; scientific services relating to the isolation and cultivation of human tissues and cells; research in the field of cell engineering technology; research in the field of vascular regeneration and repair; research and development of medicines; pharmaceutical drug development services; drug discovery services; development of pharmaceutical preparations and medicines; development of cell therapies; research and development services in the medical field of cell therapy; research and development services in the medical field of vascular regeneration and repair; clinical trials; blood analysis services; gene therapy research; information, advisory and consultancy services in relation to all of the aforesaid services.
- Class 044 — Medical, beauty and agricultural services: Regenerative medicine services; medical services; stem cell therapy services; cell therapy services; cell therapy services for vascular regeneration and repair; cell therapy services relating to the generation of human vascular reparative cells; cell therapy services relating to the injecting, grafting or implanting of cells into patients; medical services relating to the removal, treatment and processing of cells; medical services relating to the removal, treatment and processing of stem cells; stem cell storage; human cell storage; cultured cell bank services for medical transplantation; medical laboratory services for the analysis of samples taken from patients; medical analysis services; services for the testing of blood; medical services relating to the removal, treatment and processing of human blood; information, advisory and consultancy services in relation to all of the aforesaid services.
Owner
Prosecution history
- 01 Oct 2026 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
- 01 Oct 2026 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 02 Apr 2026 — REFUSAL PROCESSED BY IB
- 17 Mar 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 17 Mar 2026 — REFUSAL PROCESSED BY MPU
- 05 Mar 2026 — NEW REPRESENTATIVE AT IB RECEIVED
- 12 Feb 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 11 Feb 2026 — NON-FINAL ACTION WRITTEN
- 04 Feb 2026 — ASSIGNED TO EXAMINER
- 17 Nov 2025 — APPLICATION FILING RECEIPT MAILED
- 17 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 13 Nov 2025 — SN ASSIGNED FOR SECT 66A APPL FROM IB